Three companies met our criteria from the three 10-K annual reports filed with the SEC on 22 September 2026. To qualify, a company must have filed an annual 10-K report on the target date and have a prior-year 10-K available for a direct year-over-year comparison.
SEC What Changed Methodology
Each company is scored on how similar its current annual filing text is to the prior year. Scores run from 0 to 1 — a score of 1 means the language is essentially unchanged; a lower score means more has changed. We flag three sections that carry the most disclosure signal: Business, Risk Factors, and MD&A. Recent research suggests that lower scores indicate that a company has made significant changes to their filings, these changes are often buried in the filings. If a company was to report positive news, they would likely do so in the form of a press release or statement on their website. The large changers have often underperformed in the market, while the stable-language filers have earned positive abnormal returns.
Key Takeaways
- Readvantage Corp. (High) — Readvantage is trying to evolve from a niche reading product into a scalable API and enterprise platform, but execution and adoption risk remain high.
- AYTU BIOPHARMA, INC (Medium) — Aytu has moved from pre-launch positioning to a single-product commercial story, making EXXUA execution the key driver of the stock.
- THOR INDUSTRIES INC (Medium) — THOR is signaling a broader, more integrated operating model, with Heartland consolidation and supply businesses becoming more visible.
Ranking Table
| Rank | Company | CIK | Full Filing Similarity | Business Similarity | Risk Factors Similarity | MD&A Similarity | Most Changed Section | Assessment |
|---|---|---|---|---|---|---|---|---|
| 1 | Readvantage Corp. | 2057381 | 0.989 | 0.807 | 0.79 | 0.909 | Risk Factors | high |
| 2 | AYTU BIOPHARMA, INC | 1385818 | 0.993 | 0.988 | 0.999 | 0.999 | Business | medium |
| 3 | THOR INDUSTRIES INC | 730263 | 0.998 | 0.999 | 0.995 | 0.995 | MD&A | medium |
Readvantage Corp.
| Rank | 1 |
|---|---|
| Lowest similarity section | Risk Factors |
| Assessment | high |
| SEC filings | 2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text) |
Readvantage is no longer presenting itself mainly as a small digital reading app. It now says it is generating revenue from API subscriptions and is aiming to become a broader reading-technology platform for enterprises, developers, and white-label partners. The risk section was updated to reflect that shift, with more emphasis on scaling monetization, competition, technology dependence, and content expansion.
Main Changes
- The company added that it "generated revenue primarily from subscription-based API access," replacing the prior description of a development-stage business with no revenue.
- Business scope expanded from a web platform and digital library to include API access for developers and businesses, plus planned enterprise and white-label offerings.
- New product roadmap language says the company is building "reading-technology infrastructure" with configurable reading intensity, typography controls, document conversion, PDF/HTML processing, multilingual support, analytics, SDKs, and enterprise admin tools.
- Risk factors were rewritten to focus on "Revenue Generation, Ongoing Net Losses, and Monetization Scaling," "EdTech Competition and Market Acceptance," "Reliance on Complex Technology and API Integrations," and "Content Expansion and Integration Risks."
Watch Items
- The move toward API and white-label distribution suggests management sees higher-value, more scalable revenue outside the consumer book library.
- The new risk language confirms the business is still early and exposed to execution risk, customer adoption risk, and technology reliability issues.
- Content licensing and platform integration now look more important, which could raise costs and slow rollout if growth accelerates.
Important Filing Changes
Despite the fact that we are not required to provide risk factors, we consider the following factors to be risks to our continued growth and development: Our company heavily relies on advanced technology. Any technological glitches, malfunctions, or failures could disrupt the user experience, resulting in dissatisfaction and potential churn.
Risk Factors Revenue Generation, Ongoing Net Losses, and Monetization Scaling. While we have commenced commercial operations and generated revenue, we have a history of net losses and may not achieve or sustain profitability.
Because we will be limiting our marketing activities, we may not be able to attract enough customers to operate profitably. If we cannot operate profitably, we may have to suspend or cease operations. Risks associated with lack of demand for our products/services.
Risk Factors Revenue Generation, Ongoing Net Losses, and Monetization Scaling. While we have commenced commercial operations and generated revenue, we have a history of net losses and may not achieve or sustain profitability. Scaling operations requires ongoing expenditures in marketing, SEO, and platform development.
BUSINESS Business Overview Readvantage Corp. is a development stage company incorporated in Nevada on August 11, 2023 for the purpose of providing digital reading solutions globally. Readvantage Corp. is a pioneering technology company focused on transforming the reading and comprehension experience through advanced technologies and artificial intelligence.
BUSINESS Business Overview Readvantage Corp. ("Readvantage") is a Nevada company incorporated on August 11, 2023 for the purpose of providing digital reading solutions globally. Readvantage Corp. operates a web-based platform available through its website at https://readvantage.tech/.
AYTU BIOPHARMA, INC
| Rank | 2 |
|---|---|
| Lowest similarity section | Business |
| Assessment | medium |
| SEC filings | 2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text) |
Aytu’s business section now reflects that EXXUA is no longer just an upcoming launch; it is already being sold and is the centerpiece of the company’s commercial strategy. The filing also narrows the company’s continuing business around EXXUA growth and a smaller set of CNS-focused prescription products, while showing a leaner workforce than last year. Overall, the update points to a more concentrated, launch-driven business model.
Main Changes
- The company now says it "began selling EXXUA in fiscal 2026" and "made it the centerpiece of our commercial efforts," replacing the prior wording that it expected to launch EXXUA in the fourth calendar quarter of 2025.
- Aytu broadened its commercial focus from "innovative prescription products that address conditions frequently developed or diagnosed in children" to products that address "central nervous system conditions, including ADHD."
- The continuing-operations description was tightened from focusing on the "upcoming launch" of EXXUA to the "commercial launch and growth of EXXUA," signaling the product is now in market rather than pre-launch.
- Employee count declined from 83 to 76, with commercialization staff down from 52 to 45, while the company added more specific workforce diversity disclosure.
Watch Items
- EXXUA is now the company’s main commercial driver, so investors should watch early prescription uptake, reimbursement, and launch execution.
- The shift from launch preparation to launch-and-growth language suggests management is betting the business on one product, increasing concentration risk if adoption is slow.
- The smaller employee base may reflect post-divestiture streamlining, but it also means operating leverage will depend heavily on EXXUA sales ramping quickly.
Important Filing Changes
Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to build leading brands within large therapeutic markets. In June 2025, we entered into an Exclusive Commercialization Agreement (the “Commercialization Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”) to commercialize EXXUA (gepirone) extended-release tablets (“EXXUA”) in the United States.
Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team’s expertise to launch and build leading brands within large therapeutic markets. In June 2025, we entered into an Exclusive Commercialization Agreement (the “Commercialization Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”) to commercialize EXXUA ("Gepirone") extended-release tablets (“EXXUA”) in the United States.
EXXUA also exhibits no significant adverse effects on weight, blood pressure, heart rate or liver function. It is our expectation that EXXUA has the potential to serve as a major growth catalyst for us and we anticipate launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of our commercial efforts. In addition, we will continue to focus on commercializing innovative prescription products that address conditions frequently developed or diagnosed in children, including attention deficit hyperactivity disorder (“ADHD”).
Gepirone is a new chemical entity, and we believe EXXUA to be a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration (“FDA”) for the treatment of major depressive disorder (“MDD”) in adults. In fiscal 2026, we began selling EXXUA and made it the centerpiece of our commercial efforts. EXXUA has been extensively studied in over 5,000 patients and represents a new class of therapeutics to compete in the over $22 billion United States prescription MDD market.
We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. If we are unable to obtain funding on a timely basis, we may be unable to expand the market for our products or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due. …
We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. If we are unable to obtain funding on a timely basis, we may be unable to expand the market for our products or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due. As of June 30, 2026, we have a $13.0 million term loan and up to $16.0 million of secured revolving loans under the Eclipse Agreement, which includes the temporary Eclipse Incremental Advance of $1.5 million. As of June 30, 2026, $11.1 million was outstanding under the term loan and $6.1 million was outstanding under the secured revolving loan. All obligations under our loans are secured by substantially all of our existing property and assets subject to certain exceptions.
THOR INDUSTRIES INC
| Rank | 3 |
|---|---|
| Lowest similarity section | MD&A |
| Assessment | medium |
| SEC filings | 2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text) |
THOR’s filing shows a modest but meaningful business reframe. The company now highlights supply operations alongside RV manufacturing, and it is folding Heartland into Jayco for reporting purposes starting in fiscal 2026. The European description also changed, with a slightly different production footprint and brand lineup.
Main Changes
- The business description now says THOR includes supply operations, naming Airxcel and Postle, whereas the prior filing focused on RV manufacturing only.
- Heartland is no longer listed as a standalone North American operating subsidiary; it is now described as part of Jayco, with the filing noting it will be reported as a component of Jayco beginning in fiscal 2026.
- The European footprint is described differently: the new filing says THOR has eight primary RV production locations and adds Corigon to the brand list, while removing the prior reference to nine locations.
- The principal executive office address changed from 52700 Independence Ct. to 2900 Independence Ct. in Elkhart, Indiana.
Watch Items
- Adding supply operations suggests THOR is emphasizing more than vehicle assembly, which could support margin stability and a broader earnings base.
- Moving Heartland into Jayco signals an internal reorganization that may affect segment reporting and how investors track brand performance.
- The revised European footprint and brand mix point to portfolio reshaping, which matters for assessing regional exposure and execution risk.
Important Filing Changes
RISK FACTORS The following risk factors should be considered carefully in addition to the other information contained in this filing. The risks and uncertainties described below are not the only ones we face and represent risks that our management believes are currently material to our Company and our business.
RISK FACTORS The following risk factors should be considered carefully together with the other information contained in this Annual Report on Form 10-K. The risks and uncertainties described below are not the only ones we face and represent risks that management currently believes are material to the Company and its business.
RISK FACTORS The following risk factors should be considered carefully in addition to the other information contained in this filing. The risks and uncertainties described below are not the only ones we face and represent risks that our management believes are currently material to our Company and our business. Additional risks and uncertainties not presently known to us or that we currently deem not material may also harm our business.
RISK FACTORS The following risk factors should be considered carefully together with the other information contained in this Annual Report on Form 10-K. The risks and uncertainties described below are not the only ones we face and represent risks that management currently believes are material to the Company and its business. Additional risks and uncertainties not presently known to us or that we currently deem not material may also harm our business.
Unless the context otherwise requires or indicates, all references to “THOR”, the “Company”, “we”, “our” and “us” refer to THOR Industries, Inc. and its subsidiaries. Our principal North American recreational vehicle operating subsidiaries are Airstream, Inc. (“ Airstream ”), Heartland Recreational Vehicles, LLC (“ Heartland ”, which will be reported as a component of Jayco beginning in fiscal 2026), Jayco, Inc. (“ Jayco ”), Keystone RV Company (“ Keystone ”), K.Z., Inc. (“ KZ ”), Thor Motor Coach, Inc. (“ Thor Motor Coach ”) and Tiffin Motorhomes, Inc. (“ Tiffin Group ”). Our European recreational vehicle operations include nine primary RV production locations producing numerous brands within Europe, including Buccaneer, Buerstner, Carado, CrossCamp, Dethleffs, Elddis, Eriba, Etrusco, Hymer, Laika, LMC, Niesmann+Bischoff, Sunlight and Xplore.
Unless the context otherwise requires or indicates, all references to “THOR”, the “Company”, “we”, “our” and “us” refer to THOR Industries, Inc. and its subsidiaries. Our principal North American recreational vehicle operating subsidiaries are Airstream, Inc. (“ Airstream ”), Jayco, Inc. (“ Jayco ”), Keystone RV Company (“ Keystone ”), K.Z., Inc. (“ KZ ”), Thor Motor Coach, Inc. (“ Thor Motor Coach ”) and Tiffin Motorhomes, Inc. (“ Tiffin Motorhomes ”). Our European recreational vehicle operations include eight primary RV production locations producing numerous brands within Europe, including Buccaneer, Buerstner, Carado, Corigon, CrossCamp, Dethleffs, Elddis, Eriba, Etrusco, Hymer, Laika, LMC, Niesmann+Bischoff, Sunlight and Xplore.
Why SEC Filing Changes Matter
Research by Cohen et al. (Lazy Prices, 2020) — using the complete history of SEC filings from 1995 to 2014 — shows that when firms make active changes to their annual disclosures, those changes convey an important signal about future operations and returns. A portfolio that shorted "changers" and bought "non-changers" earned over 22% per year in annual alpha historically. Changes to the Risk Factors section, Business description, and language referring to the executive team were especially informative. Critically, these returns accrued gradually as information was later revealed through news and earnings — not at the time of filing — suggesting many investors remain inattentive to these simple, public signals. This snapshot is a starting point for deeper investigation, not a buy or sell recommendation.
For more like this, see the full SEC What Changed archive, browse more equity research reports, or subscribe to Quantitative Research Notes for new filing-change alerts as soon as they publish.
Leave a Comment